Published in J Am Soc Nephrol on April 02, 2008
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med (2014) 1.14
Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol (2010) 1.14
Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes (2012) 1.08
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol (2012) 1.07
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults. BMC Nephrol (2011) 0.94
The relationship between epicardial adipose tissue and malnutrition, inflammation, atherosclerosis/calcification syndrome in ESRD patients. Clin J Am Soc Nephrol (2011) 0.92
Neck circumference, along with other anthropometric indices, has an independent and additional contribution in predicting fatty liver disease. PLoS One (2015) 0.89
Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med (2015) 0.89
Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract (2014) 0.88
Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc (2013) 0.88
Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One (2014) 0.85
Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatr Nephrol (2009) 0.85
Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig (2013) 0.82
NAFLD and Chronic Kidney Disease. Int J Mol Sci (2016) 0.79
Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol (2012) 0.79
Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis. J Nephrol (2015) 0.78
Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol (2016) 0.77
Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med (2013) 0.77
The Age-Specific Association of Waist Circumference and Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus in Shandong, China. Int J Endocrinol (2015) 0.77
Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res (2017) 0.75
The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One (2017) 0.75
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med (2003) 23.33
Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med (2006) 20.27
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes (2005) 5.22
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Nephropathy in diabetes. Diabetes Care (2004) 4.08
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes (2005) 3.36
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care (2006) 2.04
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 1.95
gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem (2006) 1.94
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes (2004) 1.92
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care (2004) 1.79
Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (2006) 1.65
Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol (2006) 1.61
Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med (2007) 1.57
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int (2006) 1.40
Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol (2006) 1.30
Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab (2005) 1.26
Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep (2006) 1.20
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut (2005) 1.19
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev (2006) 1.19
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia (2005) 1.17
Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol (2003) 1.16
Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med (2004) 1.15
Diabetic nephropathy: prevention and treatment. Kidney Int (2001) 1.10
Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol (2006) 1.03
Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care (2003) 0.98
Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia (2006) 0.95
Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care (2007) 0.88
The liver is the main site for metabolism of circulating advanced glycation end products. J Hepatol (2002) 0.85
Treating hypertension in the patient with overt diabetic nephropathy. Semin Nephrol (2007) 0.77
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Do clinicians decide relying primarily on Bayesians principles or on Gestalt perception? Some pearls and pitfalls of Gestalt perception in medicine. Intern Emerg Med (2014) 3.93
Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med (2009) 3.84
Rapid kidney function decline and mortality risk in older adults. Arch Intern Med (2008) 3.54
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes (2005) 3.36
Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes (2004) 2.89
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
Acquired factor VIII inhibitors. Blood (2008) 2.67
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care (2002) 2.38
25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis (2008) 2.36
25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension (2010) 2.33
Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology (2013) 2.28
Biochemical markers of muscular damage. Clin Chem Lab Med (2010) 2.25
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med (2010) 2.20
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: meta-analysis of available studies. Int J Cardiol (2012) 2.07
Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) (2006) 2.05
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care (2006) 2.04
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care (2007) 2.03
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Increased fructose associates with elevated blood pressure. J Am Soc Nephrol (2010) 2.01
Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation (2002) 1.97
Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis (2006) 1.96
Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care (2003) 1.88
Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis (2011) 1.83
Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis (2012) 1.81
Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care (2004) 1.79
Chronic kidney disease is associated with incident cognitive impairment in the elderly: the INVADE study. Nephrol Dial Transplant (2009) 1.78
Dietary sodium restriction reverses vascular endothelial dysfunction in middle-aged/older adults with moderately elevated systolic blood pressure. J Am Coll Cardiol (2012) 1.77
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis (2005) 1.69
The order of draw: myth or science? Clin Chem Lab Med (2013) 1.66
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med (2011) 1.65
Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med (2013) 1.63
Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus (2009) 1.62
Red blood cell distribution width is significantly associated with aging and gender. Clin Chem Lab Med (2014) 1.58
Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: the CACTI study. Diabetes Care (2013) 1.58
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost (2012) 1.57
Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care (2003) 1.57
Preanalytical phase--a continuous challenge for laboratory professionals. Biochem Med (Zagreb) (2012) 1.56
How I treat rare venous thromboses. Blood (2008) 1.56
Development of a novel, hemolysis-resistant reagent for assessment of α-amylase in biological fluids. Clin Chem Lab Med (2013) 1.54
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Laboratory medicine does matter in science (and medicine)… yet many seem to ignore it. Clin Chem Lab Med (2015) 1.53
Biomedical research platforms and their influence on article submissions and journal rankings: an update. Biochem Med (Zagreb) (2012) 1.53
Serum leptin level and the risk of nontraumatic fracture. Am J Med (2004) 1.53
Relationship between abnormal microvolt T-wave alternans and poor glycemic control in type 2 diabetic patients. Pacing Clin Electrophysiol (2007) 1.52
Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone (2006) 1.50
Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.50
Quality and reliability of routine coagulation testing: can we trust that sample? Blood Coagul Fibrinolysis (2006) 1.50
Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. Clin Lab (2009) 1.49
Effects on health of air pollution: a narrative review. Intern Emerg Med (2015) 1.48
Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol (2008) 1.48
Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis (2011) 1.47
The syndrome of the "obsessive-compulsory scientist": a new mental disorder? Clin Chem Lab Med (2013) 1.47
Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis (2006) 1.45
Higher systolic blood pressure is associated with progression of carotid intima-media thickness in patients with chronic kidney disease. Kidney Int (2010) 1.45
Should women with abnormal serum thyroid stimulating hormone undergo screening for anemia? Arch Pathol Lab Med (2008) 1.45
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci (2014) 1.44
New ways to deal with known preanalytical issues: use of transilluminator instead of tourniquet for easing vein access and eliminating stasis on clinical biochemistry. Biochem Med (Zagreb) (2011) 1.43
The influence of polyvascular disease on the obesity paradox in vascular surgery patients. J Vasc Surg (2010) 1.43
Iron and thrombosis. Ann Hematol (2007) 1.43
The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension (2008) 1.42
Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion (2004) 1.42
The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med (2011) 1.42
Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis (2007) 1.42
The baseline serum value of α-amylase is a significant predictor of distance running performance. Clin Chem Lab Med (2015) 1.42
Phlebotomy issues and quality improvement in results of laboratory testing. Clin Lab (2006) 1.41
Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma. Clin Chem (2006) 1.40
The health risks of acute exercise should also matter to internal medicine. Eur J Intern Med (2011) 1.40
Is laboratory medicine a dying profession? Blessed are those who have not seen and yet have believed. Clin Biochem (2010) 1.40